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Abstract
An essential component of the neural network regulating ingestive behavior is the brain 5-
hydroxytryptamine2C receptor (5-HT2CR), agonists of which suppress food intake and were
recently approved for obesity treatment by the US Food and Drug Administration. 5-HT2CR-
regulated appetite is mediated primarily through activation of hypothalamic arcuate nucleus
(ARC) pro-opiomelanocortin (POMC) neurons, which are also disinhibited through a 5-HT1BR-
mediated suppression of local inhibitory inputs. Here we investigated whether 5-HT2CR agonist
anorectic potency could be significantly enhanced by coadministration of a 5-HT1BR agonist and
whether this was associated with augmented POMC neuron activation on the population and/or
single-cell level. The combined administration of subanorectic concentrations of 5-HT2CR and 5-
HT1BR agonists produced a 45% reduction in food intake and significantly greater in vivo ARC
neuron activation in mice. The chemical phenotype of activated ARC neurons was assessed by
monitoring agonist-induced cellular activity via calcium imaging in mouse POMC-EGFP brain
slices, which revealed that combined agonists activated significantly more POMC neurons (46%)
compared with either drug alone (~25% each). Single-cell electrophysiological analysis
demonstrated that 5-HT2CR/5-HT1BR agonist coadministration did not significantly potentiate the
firing frequency of individual ARC POMC-EGFP cells compared with agonists alone. These data
indicate a functional heterogeneity of ARC POMC neurons by revealing distinct subpopulations of
POMC cells activated by 5-HT2CRs and disinhibited by 5-HT1BRs. Therefore, coadministration of
a 5-HT1BR agonist potentiates the anorectic efficacy of 5-HT2CR compounds by increasing the
number, but not the magnitude, of activated ARC POMC neurons and is of therapeutic relevance
to obesity treatment.
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Introduction
Obesity is a primary global health challenge of the 21st century, with obesity
pharmacotherapies representing one of the most profound unmet clinical needs. The
dynamic interplay between nutritional intake and the biogenic amine 5-hydroxytryptamine
(5-HT), which is derived from the essential dietary amino acid tryptophan, indicates that 5-
HT is inextricably linked to energy balance (Fernstrom and Wurtman, 1972; Tecott, 2007).
Compounds augmenting the bioavailability of 5-HT by blocking its reuptake and/or
stimulating release, such as D-fenfluramine and sibutramine, have been at the forefront of
obesity treatment for the past 15 years (Lam et al., 2010). However, such compounds have
been withdrawn from clinical use due to off-target effects (Connolly et al., 1997). Therefore,
a greater understanding of the cellular networks that underlie the effectiveness of these
compounds would aid in maximizing their therapeutic potential and facilitating the
generation of more effective 5-HT obesity therapies.
Past efforts revealed that D-fenfluramine requires functional Gq-coupled 5-HT2C receptors
(5-HT2CRs) and Gi-coupled 5-HT1B receptors (5-HT1BRs) to suppress appetite (Tecott et
al., 1995; Lucas et al., 1998). Through these receptors, D-fenfluramine modulates the
melanocortin system of the arcuate nucleus of the hypothalamus (ARC), a key energy
balance network (Heisler et al., 2002, 2006; Sohn et al., 2011). 5-HT-mediated appetite
through the engagement of the ARC melanocortin system occurs via a three-pronged
mechanism: (1) direct activation of anorectic pro-opiomelanocortin (POMC) neurons (the
endogenous melanocortin receptor agonist) via 5-HT2CRs, (2) indirect 5-HT1BR-mediated
disinhibition of anorectic POMC neurons via suppression of local inhibitory inputs, and (3)
direct inhibition of orexigenic agouti-related protein (AgRP) neurons (the endogenous
melanocortin receptor antagonist/inverse agonist; Heisler et al., 2002, 2006; Sohn et al.,
2011). Furthermore, 5-HT2CR action exclusively on POMC neurons is required for D-
fenfluramine to exert its anorectic effect (Xu et al., 2008, 2010), demonstrating the
therapeutic relevance of the 5-HT-melanocortin axis. Indeed, the significance of this system
in energy balance regulation was realized in the summer of 2012 when the US Food and
Drug Administration approved a 5-HT2CR agonist (Lorcaserin; Arena Pharmaceuticals) for
obesity treatment.
Here we investigated means with which to improve the anorectic therapeutic profile of this
new class of obesity pharmacotherapy. In light of 5-HT’s bimodal activation of ARC POMC
neurons via its concerted action at 5-HT2CRs and 5-HT1BRs, we examined whether a net
gain in 5-HT2CR agonist anorectic effect could be obtained by coadministration with a 5-
HT1BR agonist and, if so, whether this was associated with increased efficacy of POMC
neuron activation on either the population or single-cell level.
Materials and Methods
Animals
Transgenic mice on a C57BL/6 background expressing enhanced green fluorescent protein
(EGFP) under the control of POMC regulatory elements (POMC-EGFP mice; generous gift
from Profs. Richard Simerly and Malcolm Low; Heisler et al., 2002) and wild-type C57BL/
6 mice were group housed and maintained on a 12:12 light-dark cycle (lights on at 0700)
with ad libitum access to chow diet and water unless otherwise stated. All experiments were
in accordance with the UK Animals (Scientific Procedures) Act 1986.
Drugs
(4aR)-8,9-Dichloro-2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5(6H)-one
(WAY-161503; Tocris Bioscience) and 5-propoxy-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-
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pyrrolo[3,2-b]pyridine hydrochloride (CP-94253; Tocris Bioscience) were used as selective
5-HT2CR and 5-HT1BR agonists, respectively. Drugs were dissolved in distilled water and
administered in a volume of 10 ml/kg of body weight.
Effect of 5-HT2CR and 5-HT1BR agonists on acute food intake
Single housed C57BL/6 mice (n = 30) received a habituation intraperitoneal injection of
vehicle before a 24 h fast from 0900 h (lights on 0700/off 1900). Mice were then treated
intraperitoneally with vehicle, WAY-161503 (5, 10, 20 mg/kg), CP-94253 (5, 10, 20 mg/
kg), or a combined dose of WAY-161503 (10 mg/kg) and CP-94253 (0, 5, 10, 20 mg/kg).
One hour postinjection, chow pellets were replaced and the 4 h food intake was measured.
These studies were performed using a within-subject experimental design with a minimum 3
d treatment-free period.
Immunohistochemistry
To assess in vivo ARC neuronal activity, ad libitum fed or 24 h fasted C57BL/6 mice were
treated intraperitoneally with saline, 10 mg/kg WAY-161503, 20 mg/kg CP-94253, or
combined 10 mg/kg WAY-161503 + 20 mg/kg CP-94253 (n = 10 per treatment) for 2 h
following the onset of the light cycle (0900 h). Two hours later, mice were terminally
anesthetized, transcardially perfused with 0.9% saline and then 10% neutral buffered
formalin (Sigma), and brains were extracted, prepared, coronally sectioned (25 μm), and
processed for cFOS immunoreactivity (FOS-IR) as described previously (Alon et al., 2009;
Lam et al., 2009; Marston et al., 2011) using an anti-cFOS rabbit primary antibody (1:8000,
catalog #PC38; Calbiochem) and a biotinylated donkey anti-rabbit secondary antibody
(1:1000, catalog #711-065-152, Stratech). Images of FOS-IR were generated and analyzed
using an Axioskop II microscope (Carl Zeiss) and Adobe Photoshop CS5 software.
Quantitative analysis of manually counted FOS-IR cells was conducted at the rostral ARC
(−1.58 to −1.94 mm from bregma) and the caudal ARC (−2.18 to −2.46 mm from bregma;
Paxinos and Franklin, 2001).
Tissue preparation for calcium imaging and electrophysiology
Coronal brain slices (180 μm thick) containing the ARC (−1.58 to −1.94 mm bregma) were
taken from ad libitum fed POMC-EGFP mice 2 h after the onset of the light cycle. Slices
were prepared as described previously (Heisler et al., 2002, 2006; Blot et al., 2009) and
maintained in an artificial cerebrospinal fluid solution containing the following (in mM): 126
NaCl, 2.5 KCl, 21.4 NaHCO3, 1.2 NaH2PO4, 10 glucose, 2 Na pyruvate, 1.2 MgCl2, and 2.4
CaCl2, pH 7.3, gassed with 95% O2 and 5% CO2.
Calcium imaging
Brain slices from male and female POMC-EGFP (28 ± 1 d, n = 9) mice were loaded with
fura-2 AM (9.6 μM, 0.04% pluronic acid, 34–36°C for 20 min, followed by a 20 min
washout). Imaging was performed at 34–36°C with an Olympus FluoView 1000MPE two-
photon laser-scanning microscope, equipped with a MaiTai DeepSee laser (Spectra-Physics)
tuned to 790 nm, and via an LUMPlanFI/IR 40× (numerical aperture 0.8) objective. Images
were acquired at a frame rate of 5.4 s and spatial averages of somatic fluorescence were
monitored as agonists were applied to the bath perfusion. Fluorescence values (F) were
corrected for linear bleaching, background subtracted, and expressed as the percentage ΔF/F
baseline.
Electrophysiology
Cell-attached current-clamp recordings were performed on brain slices from male and
female (7:14) POMC-EGFP (38 ± 3 d, n = 21) mice, at 32–34°C using an EPC-10 amplifier
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and Patchmaster software (HEKA Elektronik). Action potentials were detected using
MiniAnalysis software (Synaptosoft), and interspike intervals assessed before and after bath
application of agonists and expressed as percentage change from baseline.
Data analysis
Data were analyzed with Student’s t tests, one-way ANOVA, repeated-measures ANOVA,
or χ2 followed by Tukey’s or χ2 post hoc tests where appropriate. For all analyses,
significance was assigned at p < 0.05. Data are presented as mean ± SEM.
Results
Identification of subanorectic concentrations of 5-HT2CR and 5-HT1BR agonists
5-HT2CR agonist WAY-161503 and 5-HT1BR agonist CP-94253 suppress appetite (Lee et
al., 2002; Heisler et al., 2006; Rosenzweig-Lipson et al., 2006). We first performed a dose–
response analysis for 5-HT2CR agonist WAY-161503 (5, 10, and 20 mg/kg, i.p.) and 5-
HT1BR agonist CP-94253 (5, 10 and 20 mg/kg, i.p.) to identify subanorectic concentrations
in 24 h fasted mice (n = 10 per treatment). The highest dose of WAY-161503 (20 mg/kg,
i.p.) suppressed feeding (Fig. 1A, F(3,49) = 4.247, p = 0.010) and none of the concentrations
of CP-94253 used significantly influenced 4 h food intake (Fig. 1B, F(3,50) = 1.998, p =
0.127). Nonanorectic concentrations of 10 mg/kg WAY-161503 and 5, 10, and 20 mg/kg
CP-94253 were selected for future analyses.
Combined nonanorectic concentrations of 5-HT2CR and 5-HT1BR agonists significantly
suppress food intake
To investigate the effect of a combined nonanorectic dose of a 5-HT2CR agonist with
increasing nonanorectic concentrations of 5-HT1BR agonists on acute feeding behavior, 24 h
fasted C57BL/6 mice were treated with either saline + CP-94253 (0, 5, 10, or 20 mg/kg) or
10 mg/kg WAY-161503 + CP-94253 (0, 5, 10, or 20 mg/kg) and 4 h food intake measured
(n = 10 per treatment). Again, saline, 10 mg/kg WAY-161503, and 5, 10, and 20 mg/kg
CP-94253 had no significant effect on feeding behavior alone (Fig. 1C). In contrast,
combining CP-94253 (5, 10, and 20 mg/kg) with 10 mg/kg WAY-161503 dose-dependently
enhanced 5-HT2CR agonist anorectic potency (Fig. 1C, main effect of treatment, F(1,89) =
14.686, p < 0.001; main effect of CP-94253 concentrations, F(3,89) = 7.381, p < 0.001;
interaction between treatment and CP-94253 concentration, F(3,89) = 1.382, p = 0.254).
Indeed, 10 mg/kg WAY-161503 combined with CP-94253 suppressed 4 h feeding by 26%
at 10 mg/kg (Tukey’s post hoc, p = 0.008) and suppressed feeding by 45% at 20 mg/kg
(Tukey’s post hoc, p < 0.001), despite these concentrations of CP-94253 having no
significant effect on feeding when combined with saline. These data indicate that the
efficiency of a 5-HT2CR agonist in inducing anorexia is significantly increased in
conjunction with a 5-HT1BR agonist.
Combined nonanorectic concentrations of 5-HT2CR and 5-HT1BR agonists significantly
increase ARC FOS-IR
We next sought to investigate the neural mechanism underlying the observed potentiation of
anorexia by combining a 5-HT2CR agonist with a 5-HT1BR agonist. Based on previous
reports indicating that both 5-HT2CR and 5-HT1BR agonists influence the activity of ARC
melanocortin neurons (Heisler et al., 2002, 2006; Lam et al., 2008; Sohn et al., 2011), we
first examined in vivo ARC neuronal activation using FOS-IR. We observed that
concentrations of the 5-HT2CR (10 mg/kg) and 5-HT1BR (20 mg/kg) agonists that did not
influence feeding when administered alone also did not alter ARC neuronal activity (Fig. 2).
In contrast, combined 5-HT2CR agonist (10 mg/kg) with a 5-HT1BR agonist (20 mg/kg)
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substantially increased rostral (−1.58 to −1.82 mm from bregma) ARC FOS-IR compared
with saline in both ad libitum fed (Fig. 2A–E, F(3,22) = 5.944, p = 0.0049) and 24 h fasted
mice (Fig. 2F–J, F(3,23) = 3.774, p = 0.027, n = 6–7 per treatment). Neither individual nor
combined drug treatment significantly influenced the activity of caudal (−2.18 to −2.46 mm
from bregma) ARC neurons in either ad libitum fed (saline, 118.4 ± 16.3; WAY-161503,
133.5 ± 13.0; CP-94253, 121.3 ± 25.5; WAY-161503 + CP-94253, 155.0 ± 22.2 FOS-IR
neurons, F(3,23) = 0.808, p = 0.504) or 24 h fasted mice (saline, 84.2 ± 11.1; WAY-161503,
92.3 ± 8.7; CP-94253, 63.0 ± 9.5; WAY-161503 + CP-94253, 91.3 ± 8.4 FOS-IR neurons,
F(3,24) = 2.134, p = 0.126). These data suggest that the population of ARC neurons activated
by 5-HT2CR and 5-HT1BR agonists lie in a particular subregion of the ARC, the rostral
portion.
Combined 5-HT2CR and 5-HT1BR agonists significantly increase the number of responsive
ARC POMC neurons
To clarify the chemical phenotype of rostral ARC neurons activated by combined 5-HT2CRs
and 5-HT1BRs agonists, we examined changes in intracellular calcium concentrations in
acute brain slices from POMC-EGFP mice loaded with fura-2 AM using multiphoton
fluorescence imaging (Fig. 3A). Approximately 25% of POMC neurons responded to 20 μM
WAY-161503 (12 of 45) and 200 nM CP-94253 (19 of 66) alone. In contrast, by combining
20 μM WAY-161503 with 200 nM CP-94253, ~46% of ARC POMC neurons (34 of 74) were
responsive, significantly more than individual agonists alone (Fig. 3B,C, χ2 (2) = 6.38, p =
0.041, n = 185). Illustrating that CP-94253’s effects on POMC activity are mediated via
presynaptic action at 5-HT1BRs, both the synaptic blocker tetrodotoxin (1 μM) and the
GABAA receptor antagonist gabazine (3 μM) prevented CP-94253’s effects on POMC
activity (0 of 27 and 3 of 42, respectively, χ2 (2) = 15.4, p < 0.001, compared with
CP-94253 alone, n = 135), whereas gabazine (3 μM) did not influence WAY-161503’s effect
(χ2 (1) = 0.971E-02, p = 0.922, compared with WAY-161503 alone, n = 53; Fig. 3B). These
findings are consistent with previous reports indicating that a 5-HT2CR agonist activates
~25% of POMC neurons (Sohn et al., 2011) and reveal for the first time the proportion of
POMC neurons activated by a 5-HT1BR agonist. The finding that the 5-HT2CR agonist and
5-HT1BR agonist activated a similar percentage of POMC neurons illustrates the importance
of modulating GABAergic tone on POMC activity in 5-HT’s appetitive effects. When
combined, the 5-HT2CR and 5-HT1BR agonists significantly increased the number of ARC
POMC neurons activated on a population level.
POMC ARC neurons increase firing rate in response to individual and combined 5-HT2CR
and 5-HT1BR agonists
To explore the nature of ARC POMC neuronal activation in response to WAY-161503 and
CP-94253 on a single-cell level, we used cell-attached electrophysiological recording to
assess changes in firing frequency in acute brain slices isolated from POMC-EGFP mice.
Recordings were made from ventromedial ARC POMC neurons −1.58 to −1.94 mm from
bregma where the preponderance of 5-HT responding POMC neurons localize (Sohn et al.,
2011). Changes in firing frequency were measured as a percentage change of an interspike
interval from baseline (Fig. 4A–C). ARC POMC neurons treated with 20 μM WAY-161503
and 200 nM CP-94253 administered individually and in combination showed a substantially
higher increase in firing frequency (12.8 ± 6.5%, 25.1 ± 13.2%, and 37.7 ± 9.7%,
respectively, n = 19) and did not have a significantly different effect on the degree of POMC
neuron activation (Fig. 4D, one-way ANOVA, F(2,18) = 1.311, p = 0.297, n = 6–7 per
treatment). These data reveal that whereas combining 5-HT2CRs and 5-HT1BRs agonists
recruits a greater number of ARC POMC neurons, on a single-cell level, combined agonist
administration fails to potentiate the action of either drug alone.
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Discussion
Lorcaserin, a 5-HT2CR agonist soon to reach the clinical setting (Smith et al., 2010), was the
first new approved obesity treatment by the FDA in 13 years. Here we investigated means
with which to improve the anorectic therapeutic profile of 5-HT2CR agonists. Utilizing
concentrations of compounds that did not influence feeding, we observed that when
combining a 5-HT2CR agonist with a 5-HT1BR agonist, a significant suppression of food
intake was obtained. Illustrating a mechanism underlying this effect, we report that 5-
HT2CR and 5-HT1BR agonist coapplication produced a significant increase in the activity of
the key appetitive regulator POMC in the ARC on the population level, but not the single-
cell level.
POMC is a component of the melanocortin system and acts as a principal gateway through
which multiple metabolic cues signal (Broberger, 2005; Zhou et al., 2005; Lam et al., 2010;
Pandit et al., 2011). Indeed, both the critical appetitive neurotransmitter 5-HT and the
adipocyte-derived hormone leptin reciprocally regulate the activity of POMC and AgRP
neurons by directly activating POMC neurons, inhibiting GABAergic inputs onto POMC
neurons, and directly inhibiting AgRP neurons (Cowley et al., 2001; Heisler et al., 2002,
2006; Zhou et al., 2005). The important role of GABA in the mediation of POMC tone in
the regulation of energy balance has been revealed in a recent study demonstrating that a
primary effect of leptin on appetite and body weight is mediated directly through modulation
of GABAergic neurotransmission (Vong et al., 2011). We reported previously that half the
concentration of the 5-HT1BR agonist CP-94253 was sufficient to reduce inhibitory
postsynaptic currents onto POMC neurons compared with the concentration required to
directly inhibit the activity of AgRP neurons (Heisler et al., 2006). This is consistent with
the localization of 5-HT1BRs, which are primarily heteroreceptors influencing the release of
other neurotransmitters such as GABA (Stanford and Lacey, 1996). The in vivo feeding data
together with the calcium imaging and electrophysiological data presented here indicate that
the effect of 5-HT1BR agonists on appetite is associated with an increase in ARC POMC
neuron disinhibition via a suppression of local GABAergic inputs, and that this is as
important as direct stimulation of POMC neurons via 5-HT2CRs in mediating 5-HT-induced
anorexia.
The identification of functional heterogeneity in ARC POMC neurons was recently revealed
in a study showing that POMC neurons responsive to leptin were distinct from those
responsive to a 5-HT2CR agonist (Sohn et al., 2011). The data presented here further unravel
the functional response of POMC neurons to 5-HT2CR and 5-HT1BR agonists and suggest
an additional level of dissociation. Specifically, within the rostral ARC, individual 5-HT2CR
and 5-HT1BR agonists alone activate ~25% of POMC neurons each and, when combined,
activate ~46% of POMC neurons. Data obtained on a single-cell level reveal that 5-HT2CR
and 5-HT1BR coadministration is not more effective at activating POMC neurons than
individual agonists: they all stimulate POMC neurons to a similar extent. Together, the data
indicate that a primary effect of agonists is achieved via activation of distinct subpopulations
of POMC neurons, those expressing 5-HT2CRs (Fig. 4Ei) and those receiving inhibitory
inputs expressing 5-HT1BRs (Fig. 4Eii), agonists that when combined thereby significantly
increase the proportion of POMC neurons activated. These data provide an additional
functional dissociation of ARC POMC neurons within the rostral ARC and further clarify
the heterogeneity of this important population of cells influencing energy balance.
In summary, we report a significant reduction in food intake by combining a 5-HT2CR
agonist with a 5-HT1BR agonist at concentrations that alone do not influence feeding—a
combination of agonists that significantly increased POMC neuron activity on a population
level. The data obtained therefore provide an effective means of stimulating a greater
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proportion of these critical appetitive cells, highlight the heterogeneity of ARC POMC
neurons, and illustrate the importance of GABAergic modulation of POMC neurons in 5-
HT-induced anorexia. These data reveal a powerful means with which it is possible to
augment the anorectic potency of a new class of obesity pharmacotherapy, 5-HT2CR
agonists.
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Figure 1.
Combined WAY-161503 and CP-94253 significantly reduce feeding at concentrations that
alone are not anorectic. A, The 5-HT2CR agonist WAY-161503 (20 mg/kg, i.p.) significantly
suppresses 4 h feeding compared with vehicle (**p = 0.010). B, The 5-HT1BR agonist
CP-94253 does not significantly influence 4 h feeding. C, Combined subanorectic
concentrations of WAY-161503 (10 mg/kg) and CP-94253 (20 mg/kg) significantly
suppress 4 h food intake compared with saline and individually administrated drugs
(***p<0.001, saline+CP-94253 at 0,5,10,20mg/kg compared with 10 mg/kg
WAY-161503+CP-94253 at 0,5,10,20 mg/kg; ##p=0.008, 10 mg/kg WAY-161503+10 mg/
kg CP-94253; and ###p<0.001, 10 mg/kg WAY-161503+20 mg/kg CP-94253 compared
with saline; n = 10 per treatment).
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Figure 2.
Combined WAY-161503 and CP-94253 significantly increase ARC FOS-IR compared with
agonists administrated individually. A, F, Quantitative analysis of FOS-IR neurons in rostral
ARC (bregma levels from −1.58 mm to −1.94 mm); combination of 10 mg/kg WAY-161503
and 20 mg/kg CP-94253 increases rostral ARCFOS-IR in ad libitum fed (A) and 24 h fasted
mice (F) (*p = 0.027, **p = 0.0049 compared with saline; n = 6–7 per treatment). B–E and
G–J, Representative images of rostral ARC FOS-IR (−1.58 mm to −1.94 mm from bregma)
in ad libitum fed (B–E) and 24 h fasted (G–J) mice treated with saline (B,G), 10 mg/kg
WAY-161503 (C,H), 20 mg/kg CP-94253 (D,I), or 10 mg/kg WAY-161503 + 20 mg/kg
CP-94253 (E,J). 3V indicates third ventricle; ME, median eminence. Scale bar, 50 μm (B–
E, G–J).
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Figure 3.
Combined WAY-161503 and CP-94253 increases ARC POMC intracellular calcium
concentrations compared with individual agonists. A, Coronal ARCPOMC-EGFP brain slice
illustrating EGFP neurons (green) loaded with fura-2 (red), dual-labeling (yellow, white
arrowheads). 3V indicates third ventricle. Scale bar, 50 μm. B, Combination of 20 μM
WAY-161503 and 200 nM CP-94253 increases intracellular calcium concentrations in ARC
POMC-EGFP neurons compared with individual treatments (*p = 041, n = 185 cells). 1 μM
tetrodotoxin (TTX) and 3 μM gabazine block the effect of 200 nM CP-94253 on POMC-
EGFP activity (***p<0.001, n=135 cells), whereas 3 μM gabazine has no effect on 20 μM
WAY-161503 on POMC-EGFP cells (p=0.922, n=53 cells). C, Representative trace of
POMC-EGFP neuron increasing intracellular calcium concentrations shown by reduced
fluorescence (F) expressed as ΔF/F to the combined dose of 20 μM WAY-161503 and 200
nM CP-94253.
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Figure 4.
WAY-161503 and CP-94253 increase the firing rate of ARC POMC neurons. A,
Representative diagram of POMC-EGFP neuron interspike interval (ISI) in response to
coapplication of 20 μM WAY-161503 and 200 nM CP-94253 recorded in a cell-attached
electrophysiological configuration (white arrow, baseline trace expanded in B and black
arrow, treatment trace expanded in C). D, Application of 20 μM WAY-161503, 200 nM
CP-94253, and 20 μM WAY-161503 + 200 nM CP-94253 achieve a similar degree of
reduction in the ISI of ARC POMC-EGFP neurons (n = 6 –7 per treatment). E, Proposed
model of the mechanism through which 5-HT2CR and 5-HT1BR agonists increase ARC
POMC neuron activity. Ei, POMC neurons are directly activated by WAY-161503 via Gq-
coupled 5-HT2CRs expressed on POMC neurons. Eii, POMC neurons are disinhibited/
indirectly activated by CP-94253 via Gi-coupled 5-HT1BR-expressing GABAergic
projections onto POMC.
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